Determines the amount paid to a pharmacy for certain high cost drugs

2025 Regular Session Introduced by Jessica Scarcella-Spanton

Sets how much pharmacies are paid for high-cost drugs, shaping reimbursement and affecting insurers, PBMs, pharmacies, and patients' access and costs.

REFERRED TO HEALTH

Legislative Bill Summary: S 6323

Overview

Bill number: S 6323

Title: Determines the amount paid to a pharmacy for certain high cost drugs

Sponsor (primary): Jessica Scarcella-Spanton

Status: Referred to Health

Introduced / Date: March 10, 2025

Legislative actions: On March 10, 2025, the bill was referred to the Health committee (listed twice in the record).

Related bills (prior-session): S 6763, S 4028

Purpose and intent

The bill’s title indicates the core objective is to determine (prescribe) the amount that pharmacies are paid for certain high-cost drugs. This suggests a focus on pharmacy reimbursement for expensive medications, potentially to address affordability, access, or payer-practice disparities. The exact mechanism (e.g., a fixed rate, formula, benchmark, or negotiation framework) is not provided in the available information.

Key provisions (not specified in the provided text)

The precise definitions (which drugs are “high-cost,” how they are determined, and what constitutes “amount paid” to a pharmacy) are not included in the summary.

Details such as:

Reimbursement methodology (e.g., fixed fee, percentage of a benchmark, tiered rates)
Eligibility criteria and automatic triggers
Oversight, enforcement, and complaint processes
Transition timelines, effective dates, and applicability
Fiscal impact, savings estimates, and cost-shifts
Exemptions or special cases (e.g., compassionate use, institutional settings)

Until the full text is available, these elements remain speculative.

Who would be affected

Pharmacies dispensing high-cost drugs (reimbursed amounts would be governed by the bill if enacted).

Payers (private insurers, pharmacy benefit managers, and any state-sponsored programs) that reimburse pharmacies for high-cost medications.

Patients receiving high-cost drugs could experience downstream effects on access, affordability, and out-of-pocket costs depending on how reimbursement changes influence pricing and coverage.

Procedural and timeline aspects

Current stage: Referred to the Health committee, indicating it will be reviewed for impact on health policy and potential amendments.

Next steps: If advanced, the committee could hold hearings, propose amendments, and move the bill to further floor consideration. A fiscal note or impact analysis may accompany subsequent actions.

Related considerations

The existence of prior-session related bills (S 6763 and S 4028) suggests ongoing interest in regulating or standardizing high-cost drug reimbursements within this legislative context. Tracking subsequent actions or sponsored amendments can offer insight into policy direction.

For readers seeking more information

To understand the bill’s exact provisions, read the full text when available and view the fiscal note, sponsor memos, and committee reports. This summary reflects publicly available basic metadata and the bill’s stated purpose from the title.